Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2009

Hydra and Cubist Ally to Further Ion Channel Drugs for Pain Management

  • Cubist Pharmaceuticals is paying $5 million up front to collaborate with Hydra Biosciences on the development of ion channel drugs for pain management. Cubist will support Hydra’s internal development R&D programs with another $5 million over two years.

    Hydra’s focus has been on compounds that target the TRPA1 receptor, which is believed to have an important role in pain management. The partnership will build on existing preclinical data and pharmacology studies.

    Under the terms of the agreement, Hydra is eligible for development milestones and royalties on product sales.

     

     



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »